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Objective: To evaluate the effectiveness of misoprostol protocol on abortion of pregnancies
resulting from sexual violence.
Method: Retrospective study with a convenience sample of 253 patients with pregnancy
between 13 and 22 weeks of pregnancy who underwent legal abortion in the Hospital Pérola
Byington, São Paulo, Brazil, between January 2008 and December 2014. Doses of misoprostol
400  g (13–17 weeks of gestation) and 200 g (18–22 weeks of gestation) were administered
vaginally every 12 h. The dose was doubled after two doses of no response and maintained
for up to four days. In the absence of fetal expulsion, a second cycle of misoprostol was
conducted after a 72-h pause. The failure of misoprostol was considered complete after two
cycles without fetal elimination. The outcome was complete or incomplete fetal expulsion,
evaluated in number of days and misoprostol dose required for abortion. Data were entered
in  Microsoft Excel 2010 program.
Results: The age ranged from 11 to 44 years of age, average 22.6 ± 8.2 years of age, with the
mean gestational age of 16.8 ± 2.6 weeks. Abortion occurred in 248 cases (98.0%) with an
average of 1468.8 g of misoprostol. The analysis of the dispersion of the total dose of miso-
prostol indicates no signiﬁcant change with increasing gestational age (y = 0.9475x + 1453)
(R2 = 0.0001). The average induction time was 2.3 days and in 81.8% of the cases abortion
occurred in the ﬁrst 72 h. Excessive and immediate uterine bleeding after fetal elimination
was  observed in 2.6% of the cases.
Conclusion: Misoprostol protocol used was effective and safe for second trimester abortionin  pregnancy resulting from sexual violence.
© 2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda.
All rights reserved.
 Study conducted at the Sexual Violence Center and Legal Abortion, Hospital Pérola Byington, São Paulo, SP, Brazil.
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ttp://dx.doi.org/10.1016/j.recli.2015.04.001
413-2087/© 2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda. All rights reserved.
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Misoprostol  no  aborto  de  segundo  trimestre  em  gestac¸ões  decorrentes
de  violência  sexual:  análise  de  efetividade  de  um  protocolo  aplicado
em  servic¸o público  de  saúde  brasileiro
Palavras-chave:
Aborto legal
Violência sexual
Misoprostol
Aborto induzido
Segundo trimestre de gravidez
r  e  s  u  m  o
Objetivo: Avaliar a efetividade de um protocolo de administrac¸ão de misoprostol no aborto
de gestac¸ões decorrentes de violência sexual.
Método: Estudo retrospectivo com amostra de conveniência com 253 pacientes com gestac¸ão
entre 13 e 22 semanas que ﬁzeram aborto legal no Hospital Pérola Byington, São Paulo,
Brasil, entre janeiro de 2008 e dezembro de 2014. Foram administradas doses de misopros-
tol  de 400 microgramas (gestac¸ões de 13-17 semanas) e 200 microgramas (gestac¸ões de 18-
22  semanas), via vaginal, a cada 12 horas. A dose foi duplicada após duas doses sem resposta
e  mantida por até quatro dias. Na ausência de expulsão fetal, um segundo ciclo de miso-
prostol foi feito após pausa de 72 horas. A falha do misoprostol foi considerada após dois
ciclos completos sem eliminac¸ão fetal. O desfecho foi a expulsão fetal, completa ou incom-
pleta, avaliada em número de dias e dose de misoprostol necessária para o aborto. Dados
digitados em programa Microsoft Excel® 2010.
Resultados: A idade variou de 11-44 anos, média de 22,6 ± 8,2 anos, com idade gesta-
cional média de 16,8 ± 2,6 semanas. O aborto ocorreu em 248 casos (98%) com média de
1.468,8 microgramas de misoprostol. A análise da dispersão da dose total de misoprostol
indica que não houve variac¸ão signiﬁcativa em func¸ão do aumento da idade gestacional
(y  = 0,9475x + 1453) (R2 = 0,0001). O tempo médio de induc¸ão foi de 2,3 dias e em 81,8% dos
casos  o aborto ocorreu nas primeiras 72 horas. Sangramento uterino excessivo e imediato
após a eliminac¸ão fetal foi observado em 2,6% dos casos.
Conclusão: O protocolo de misoprostol usado se mostrou eﬁcaz e seguro para o aborto de
segundo trimestre na gravidez decorrente de violência sexual.
©  2015 Sociedade Brasileira de Reproduc¸ão Humana. Publicado por Elsevier Editora
Ltda. Todos os direitos reservados.
second edition of the protocol began to indicate doses of 400 gIntroduction
Brazilian criminal law criminalizes the practice of abortion,
except the situations covered by Article 128 establishing a
woman’s right to terminate the pregnancy resulting from
sexual violence or when there is risk of death for pregnant
women.1 Although Brazilian legislation allows abortion in
such circumstances since 1940, only in the late 1980 emerged
the ﬁrst public health services which began to offer legal abor-
tion of ﬁrst trimester pregnancies.2
Since then, there has been slow growth in Brazilian health
services committed to human and reproductive rights of
women in situations of sexual violence. But despite the
improvements, most Brazilian women still lack access to safe
and legal abortion in cases of sexual violence, particularly
when they are in the second trimester of pregnancy.2
Since 1999, the United Nations General Assembly stipu-
lates that in circumstances where abortion is not against the
law, health services should be prepared to offer termination
of pregnancy safely and at affordable conditions for women.3
Accordingly, misoprostol is one of the methods of choice for
legal interruption of pregnancies between 13 and 22 weeks.
Misoprostol is a methyl-analog synthetic of prostaglandin
PGE1, stable at room temperature and effective to pro-
mote changes in cervical immature and induce uterine
contractility.4 Prostaglandins are derived from unsaturatedmonocarboxylic fatty acids of 20 carbons, formed by two
chains and the ﬁve-carbon ring. The differentiation of the
prostaglandins occurs by variations in methylation and oxi-
dation of carbon chains with more  or fewer double bonds in
the aliphatic side chain.5
Misoprostol is known to be effective to induce abortion,
although the time required to complete the interruption of
pregnancy is greater than when the prostaglandin is asso-
ciated with mifepristone.6 Furthermore, abortion is often
painful and with more  frequent adverse effects than when
combined with mifepristona.7
In the 1980s, misoprostol started to be used in gynecology
and obstetrics after initial indication for treatment of dyspep-
sia. Compared with other prostaglandins, misoprostol has a
lower rate of side effects, with pharmacological extended aver-
age life and easier administration by different routes.8 These
features make misoprostol the medication of choice for induc-
tion of abortion, cervical preparation and induction of labor.9
In Brazil, the Ministry of Health published in 1999, the ﬁrst
misoprostol use protocol for legally induced abortion in preg-
nancies resulting from sexual violence. A dose of 200 g was
recommended vaginally every 8 h, without deﬁning the time
of treatment or management in cases of failure. In 2005, theof misoprostol vaginally every 12 h.10
This approach was maintained until 2011, when the Min-
istry of Health started to recommend different doses according
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o gestational age, to the extent that uterine responsive-
ess to misoprostol increases directly with gestational age.4
etween 13 and 15 gestation weeks, the recommended dose
ncreased to 400 g in the vaginal route every 6 to 12 h, and
ncreased to 800 g after two unsuccessful doses. Between 16
nd 22 weeks, the recommended starting dose changed to
00 g every 6–12 h, and increased to 400 g doses after two
nsuccessful doses.10
The Ministry of Health recognizes in its documents the
xtensive evidence of other protocols in the use of misoprostol
or induced abortion presenting with relatively similar rates of
uccess and security for women.10 Thus, it recognizes that the
se of misoprostol should consider the experience gained by
he health services.
There is little information of Brazilian health services on
he termination of pregnancy resulting from sexual violence.
urthermore, most of these health care services restrict these
ases up to 12 weeks of pregnancy. In Brazil, few publica-
ions abord the management of second quarter pregnancy
ith misoprospol under sexual violence circumstance. Thus,
he objective is to evaluate the effectiveness of a misopros-
ol protocol on abortion of pregnancies resulting from sexual
iolence.
ethod
tudy  design
escriptive and retrospective study with convenience samples
f 253 women with pregnancy resulting from sexual violence,
ith gestational age between 13 and 22 weeks and who under-
ent Legal Abortion in Hospital Pérola Byington, São Paulo,
razil, between January 2008 and December 2014.
riteria  for  selection  and  inclusion  of  subjects
dult women and adolescents who sought legal interruption
f pregnancy were included based on the item II of Arti-
le 128 of the Brazilian Penal Code, which establishes the
bsence of crime and punishment when abortion is con-
ented and practiced by doctor in pregnancies resulting from
exual crime. Patients with obstetric ultrasound examination
ith gestational age between 13 and 22 weeks, living fetus
nd estimated weight less than 500 g were included in this
esearch, according to the World Health Organization deﬁni-
ion of abortion.11
The characterization of sexual crime has considered the
atients’ and their legal representatives’ reports consistent
ith Articles 213 and/or 217-A of the Brazilian criminal law.
rticle 213 criminalizes crime of rape as any sexual act not
onsented, and practiced with use of physical force and/or
erious threat. Article 217-A of vulnerable crime of rape
ncludes sexual acts against children and adolescents younger
han 14 years of age, or against those of any age who cannot
ffer resistance or valid consent.1 These two items feature the
ituations of sexual violence, a necessary criterion for the legal
ermination of pregnancy.
The approval of abortion was the result of the interdis-
iplinary team consensus upon fulﬁllment of regulations of 9(3):105–111 107
the ordinance MH/MG No. 1508, the Ministry of Health, which
provide for the supporting procedures and pregnancy termi-
nation authorization under the Uniﬁed Health System (SUS). It
was not required to provide police report or results of forensic
examination for the approval of the procedure.10
The induction of abortion exclusively used misoprostol and
had no association with other physical or medical method
according to Hospital Pérola Byington Protocol between the
period of January 2008 and December 2014. Initial doses
of 400 g of misoprostol were administered to pregnancies
between 13 and 17 weeks and 200 g in pregnancies between
18 and 22 weeks. The tablets were applied in lateral vaginal
fornix every 12 h. The initial dose was doubled to 800 and
400 g for gestational ages between 13–17 weeks and 18–22
weeks, respectively, after administration of two  consecutive
doses with no uterine response and fetal deletion, maintained
for up to four days.
In cases where there was no fetal expulsion, a second
induction cycle with misoprostol was performed after a
72-h pause at doses of 800 and 400 g for pregnancies between
13–17 weeks and 18–22 weeks, respectively, every 12 h, admin-
istered vaginally, for four days. The absence of fetal expulsion
after two complete cycles of treatment was adopted as the
criterion for induction failure. The possibility of failure by
misoprostol was notiﬁed to patients prior to initiation of
treatment and for such cases abortion was concluded by
laparotomy, anterior longitudinal hysterectomy, and fetal pla-
cental extract.
Abortion was considered complete when the clinical
inspection proved compatible with expulsion of the fetus,
placenta, umbilical cord and membranes, accompanied by
reduction in uterine volume, progressive closure of the cervix
within 24 h and absence of abnormal uterine bleeding.
In suspicion of ovular remains, the ultrasound was made
within the ﬁrst 12 hours. The abortion was considered com-
plete when there was empty uterine cavity and endometrial
thickness below 15 mm in longitudinal section. In other cases,
the utrasonography was performed seven to ten days after the
abortion during follow-up of the procedure.
Instruments
Data were collected from the database organized in Microsoft
Excell® 2010. The program database power was accomplished
through additional pre-coded card adopted by the hospital.
Each case included was previously submitted to review the
consistency of information before typing and discrepancies
which may be identiﬁed were corrected in the complemen-
tary record. After entering the data in Microsoft Excel® 2010
spreadsheet, a second review was conducted to identify pos-
sible typing errors.
Statistical  analysis
The study endpoint was the complete or incomplete fetal
expulsion, evaluated in number of days and misoprostol dose
required for abortion. Dispersion analysis was employed to
evaluate the dose of misoprostol required for fetal delivery as
a function of gestational age.
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Ethical  aspects
The study was approved by the Research Ethics Committee of
the Hospital Pérola Byington, Protocol No. 034/11, in Septem-
ber 2011, according to Resolution of the National Health
Council (Conselho Nacional de Saúde-CNS) No 196/96. For
being a study based on a sample of convenience and con-
solidated database, it was not necessary to obtain Terms of
Consent.
The database used did not include the name, initials,
identiﬁcation, medical record number or any other form of
registration that would allow the identiﬁcation of patients,
to ensure the conﬁdentiality and secrecy of information. All
women and adolescents received medical, social and psycho-
logical counseling, including guidance on ethical and legal
issues relating to abortion.
Results
The 253 cases studied corresponded to 38.5% of the total of 657
legal abortions by sexual violence carried out from January
2008 to December 2014. The age of patients ranged from 11
to 44 years, with an average of 22.6 ± 8.25. Teens (10–19 years
of age) accounted for 94 cases (37.1%) and adult women
(≥20 years) for 159 cases (62.9%). Gestational age ranged
between 13 and 22 weeks, 16.8 ± 2.6 media weeks.
The misoprostol was effective in inducing abortion in 248
cases (98.0%) requiring, on average, 1468.8 g and an average
induction time of 2.3 days. The abortion was classiﬁed as total
in 196 cases (77.5%). The analysis of the dispersion of the
total dose of misoprostol required for fetal expulsion showed
no signiﬁcant variation as a function of increasing gestational
age (y = 0.9475x + 1453) (R2 = 0.0001) (Fig. 1).
The distribution of number of days required for induction
termination of pregnancy showed that in 162 cases (61.6%)
abortion occurred in the ﬁrst 48 h (Fig. 2). The accumulated
rate in 72 h was 81.8%, equivalent to 207 cases.
Abnormal uterine bleeding, excessive and immediately
after fetal elimination, was observed in seven cases (2.6%). In
four cases (1.6%) bleeding was controlled with usual measures
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Fig. 1 – Dispersion of the total dose of misoprostol administered
weeks. Hospital Pérola Byington, São Paulo, Brazil (2008–2014).;2 9(3):105–111
to promote uterine contractility and complementary evacua-
tion by curettage without need for blood transfusion. In three
other cases (1.2%), it was necessary, in addition to previous
measures, the use of red blood cells to correct the blood loss,
but without further sequelae. No other complications were
identiﬁed.
Discussion
Sexual violence is a serious violation of human rights and
a major public health problem, representing the extreme
restriction of sexual and reproductive autonomy of women.2
Regardless of the legal deﬁnition adopted in each country,
sexual violence is recognized by the World Health Organi-
zation (WHO) as any sexual act, attempted or completed
without the consent of the victim, exercised through coercion
or intimidation, with use of physical force, threat, weapons or
psychological fear.12
Although no one knows the exact prevalence of sex-
ual violence, studies point to a worldwide problem of great
magnitude and rapid growth.13 Women who suffer sexual
crimes pose a signiﬁcant hazard to health problems, including
physical trauma, mortality, sexual dysfunction, severe psycho-
logical damage, sexually transmitted diseases and forced and
unwanted pregnancy.14
In Brazil, the number of women who resort early to emer-
gency services after sexual crime has increased, although it
is acknowledged that most of the victims do not seek for
medical care when there are no physical injuries. In three
studies, in Brazilian urban centers, between 80% and 95% of
women enrolled within 72 h of sexual violence.15 Quick access
to health services allows important intervention measures,
such as preventing unwanted pregnancy with the use of emer-
gency contraception.
However, there is evidence that different phenomenon
occurs when sexual violence results in pregnancy. Study by
Blake et al. identiﬁed different factors that can slow the search
of Brazilian women for the legal termination of pregnancy. In
pregnancies between 13 and 22 weeks, the low education and
women’s state of vulnerability were associated with this late
search. However, victims of violence whose perpetrator was
2221201918
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elated to them were the ones who  found greater barriers to
et to health care.16
Anyway, due to ignorance of their rights or access barriers
o health insurance, many  women, convinced in interrupting
heir pregnancy resulting from sexual violence, resort to illegal
bortion procedures often carried out in unsafe conditions.2
Since the International Conference on Population and
evelopment in Cairo in 1994, abortion was declared a serious
ublic health problem.3 In 2003, 20 million unsafe abor-
ions were performed in the world. In 2008, that number
ncreased to 22 million, while the overall abortion rate has not
een changed since 2000. Of these unsafe abortions, 98% are
racticed in developing countries, resulting in 47,000 mater-
al deaths and ﬁve million women with complications and
equelae.17
Complications of unsafe abortion mainly include uterine
leeding, septicemia and peritonitis. Between 20 and 30% of
nsafe abortions cause infection, and between 20 and 40%
f the cases end in severe pelvic infection.17 The risk of death
ssociated with unsafe abortion shows variation in different
egions. The abortion mortality rate is 460 per 100,000 proce-
ures in Africa in general, and 520 per 100,000 in sub-Saharan
egion. In Asia it is 160 per 100,000 and in Latin America 30 per
00,000.17
On the other hand, induced abortion performed by skilled
ealth professionals and employing appropriate techniques,
n an environment with adequate resources, is considered a
igh security procedure.17 In the US, the average rate of lethal-
ty of the legal termination of pregnancy is 0.7 deaths per
00,000 procedures. In abortion with gestational age less than
ine weeks mortality is 0.1 per 100,000 procedures ten times
ower than that observed for spontaneous ﬁrst trimester abor-
ion. In pregnancies between 16 and 20 weeks the rate rises to
.4 per 100,000, lower than the unsafe abortion.18
Misoprostol protocol analyzed in this study is similar to
hat proposed by the Latin American Federation of Obstet-
ics and Gynecology Societies (FLASOG) recommending initial
aginal dose of 400 g for termination of pregnancy between).
13 and 15 weeks, and 200 g between 16 and 20 weeks. These
doses are repeated every six to 12 h and doubled after two
doses with no success, and maintained at every 12 h up to the
maximum of four doses.4
The bioavailability of misoprostol when administered by
the vaginal route is about three times greater than the oral
route. The vaginal route progressively reaches a maximum
plasma concentration from 60 to 120 min, followed by a slow
decline that reaches 60% of baseline levels after 240 min. The
plasma levels remain relatively stable for at least 6 h after
the administration.19 The vaginal route proves more  effective
than the oral route and results with higher doses of misopros-
tol orally are similar to those observed with lower doses via
vaginal route.20
The results of the efﬁcacy of misoprostol studies to induce
abortion show great variation, especially by employing differ-
ent administration schemes. In general, the success rate with
complete expulsion of pregnancy is about 90% in both the ﬁrst
and second trimester of pregnancy. If the success criteria is
fetal expulsion, even if incomplete, success exceeds 90%.4 The
reduction in the efﬁcacy of misoprostol in the presence of vagi-
nal and cervical infections is still unclear and contradictory
data.21
In this study, we adopted the criterion of complete or
incomplete fetal expulsion, as an indicator of the success of
inducing abortion. This explains, in part, the high efﬁciency
of 98% in the termination of pregnancy resulting from sex-
ual crime. Another aspect to be considered is the handling
time for up to two cycles, and the use of up to eight doses per
cycle, to the extent that there is evidence that better results are
obtained by longer waiting time and the days of treatment.7
However, the results do not seem to be inﬂuenced by age,
ethnicity, or previous pregnancy.4
In this study, the highest percentage of fetal expulsion of
the cases occurred in the ﬁrst 24 h of treatment, with 35.5% of
total interruptions. In addition, 81.8% fetal deletion occurred
in the ﬁrst 72 h. These ﬁndings agree with the observations of
other authors.7,22–24
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There are few conditions that limit the use of misoprostol,
such as severe liver dysfunction, coagulopathy or anticoag-
ulant use, and prior history of allergy to prostaglandins.25
The adverse effects of misoprostol are not usually severe.
Vaginal bleeding and pain in the hypogastrium are present
in most cases of uterine contractility result, similar to what
occurs in spontaneous abortion.4 Other effects include nau-
sea, vomiting and diarrhea in 10–30% of inductions.24,26 These
manifestations are more  common in high doses, short inter-
vals between doses, and use of oral or sublingual route. Fever
can also occur with or without chills.27
The complication described as more  frequent in induced
abortion with misoprostol is excessive vaginal bleeding, gen-
erally higher than it occurs in the normal menstruation.
However, the bleeding is usually not higher than it occurs in
spontaneous abortion.28 The occurrence of prolonged or heavy
bleeding is expected in 1–10% of abortions with misoprostol.4
In this study abnormal bleeding occurred in 2.6% of the cases
within the limits described in other studies.
The failure of the method can also be considered a compli-
cation, considering the teratogenicity risk with misoprostol
exposure in the ﬁrst trimester of pregnancy.4 For the women
evaluated in this study the failure of 2%, even being consid-
ered low, implies in keeping the pregnancy due to rape and it
is not acceptable in these circumstances. In these cases, the
termination of pregnancy was done by laparotomy and hys-
terectomy as recommended by the regulations of the Ministry
of Health.10
Another exceptional complication with the use of miso-
prostol, but more  serious, is uterine rupture, especially in
women with previous cesarean section or previous uterine
surgery. However, these conditions are not contraindications
to the use of misoprostol in up to 22 weeks abortion. Fur-
thermore, evidence suggests that uterine rupture is related to
high doses of misoprostol or its use at shorter intervals than
recommended.29
It is desirable that the misoprostol dose be individualized
for different gestational ages, based on the evidence that the
uterine response increases directly with gestational age.4 This
proposition was adopted in the analyzed protocol in this study
to induce the second trimester abortion with smaller doses for
gestational ages between 18 and 22 weeks.
In this regard, the analysis of the dispersion of the total
dose of misoprostol required for abortion showed no signif-
icant variation as a function of increasing gestational age
(y = 0.9475x + 1453) (R2 = 0.0001). For both groups of gestational
age similar doses of misoprostol were required, averaging
1468.8 g. However, the use of lower doses in pregnancies
between 18 and 22 weeks may be an important factor to reduce
the risk of uterine rupture, usually associated with higher
doses of the drug.
Conclusions
The protocol analysis of misoprostol was shown as effective
and safe to induce abortion in pregnancies resulting from
rape. In most cases it occurred in the ﬁrst few days of induc-
tion for abortion in a complete manner. Abnormal uterine
bleeding complication was found in the frequency reported;2 9(3):105–111
in the literature. These cases were treated with measures to
promote contractility and emptying complements without
sequelae have been registered.
Conﬂicts  of  interest
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